Thiometsalatum veterinary grade API is handled as a crystalline sodium organomercurial with a mercury fraction close to 49.6% w/w. The antimicrobial activity in aqueous formulations depends on release of ethylmercuric ion, which binds to sulfhydryl-bearing enzyme systems in bacterial and fungal cells. In multi-dose vaccine and antiserum filling suites, thiomersal is metered from a concentrated aqueous stock solution at 0.5% w/v into post-antigen bulk, yielding final concentrations of 0.005% w/v to 0.01% w/v, equivalent to 50–100 µg/mL. The addition point is post-antigen blending and before aseptic filtration through a 0.22 µm PVDF membrane. Terminal steam sterilisation at 121 °C is not used because organomercurial degradation accelerates and ethylmercury volatilises under autoclave conditions. The bulk holding vessel is fabricated from 316L stainless steel with an electropolished product-contact finish. Headspace oxygen is displaced by nitrogen overlay. Uncoated halobutyl rubber stoppers adsorb thiomersal from the finished liquid; the closure is therefore specified as a fluoropolymer-coated chlorobutyl elastomer with a low extractable sulfur profile. Preservative efficacy is challenged according to Ph. Eur. 5.1.3 or USP <51>, using inocula of 10^5–10^6 CFU/mL of Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans and Aspergillus brasiliensis. For parenteral multi-dose claims, Ph. Eur. 5.1.3 requires 1 log bacterial reduction at 24 h, 3 log at 7 d and no increase at 28 d; USP <51> category 1 criteria require 1 log at 7 d, 3 log at 14 d and no increase at 28 d. Fungal counts must not increase in either protocol. Thiomersal is incompatible with sulfites, sodium metabisulfite, cysteine, glutathione and hydrogen sulfide; contact with these reducing agents produces elemental mercury as a grey precipitate. The stock solution is buffered to pH 6.5–7.5; below pH 5 thiosalicylic acid may precipitate and above pH 8 degradation accelerates. Bacterial endotoxin control is verified by Ph. Eur. 2.6.14 or USP <85>. The filling line must avoid cleaning agents that leave sulfite residues. Aseptic processing remains mandatory under 21 CFR 211.113(b); thiomersal functions as a bioburden control for repeated withdrawal, not as a sterilant.

What governs the upper thiomersal concentration in multi-dose ophthalmic and otic products for companion animals?

Multi-dose ophthalmic and otic solutions use a lower thiomersal concentration than injectable biologicals, typically 0.001% w/v to 0.004% w/v, equivalent to 10–40 µg/mL. The upper limit is controlled by corneal tolerability and preservative challenge performance, not merely by solubility. A 10 mL low-density polyethylene dropper with a pierced tip delivers 25–50 µL per instillation. The vehicle for ophthalmic use is buffered to pH 6.8–7.4; otic formulations may be acidified to pH 5.0–6.0 to reduce tissue irritation and prolong stability. Above pH 8, decomposition is visible as grey mercury precipitation, so borate-based buffers are avoided when the vehicle is autoclaved before API addition. Blow-fill-seal ampoules of low-density polyethylene or polypropylene eliminate the rubber stopper adsorption observed with vials. Filtration is performed with a 0.22 µm PVDF or PES membrane; nylon membranes can exhibit high binding. Nonionic surfactants above their critical micelle concentration sequester thiomersal into micelles and reduce the free aqueous concentration, so polysorbate 80 and similar high-HLB surfactants must be justified by challenge testing. Preservative efficacy testing follows Ph. Eur. 5.1.3 or USP <51>. The primary stability risk is photochemical cleavage of the carbon-mercury bond under UV light; amber packaging and light-protected storage are used. Residual oxygen in dropper bottles can be reduced with nitrogen flushing. The product remains acceptable only if the dropper tip is not touched to the cornea, skin or ear canal, because the preservative reservoir is not designed to sterilise a contaminated tip.

A hydroalcoholic topical tincture is compounded by dissolving thiomersal at 0.1% w/v in a vehicle containing 50% v/v ethanol and 10% v/v acetone. Sodium borate is included as a stabiliser and the liquid is filtered through a 0.45 µm polypropylene cartridge before filling into amber Type III glass. The ethanol-acetone vehicle provides rapid drying on intact skin and leaves a thiomersal film with residual antimicrobial action. Aqueous pump-spray products at 0.05% w/v are packed in fluorinated high-density polyethylene containers to reduce adsorption. Process controls include addition of thiomersal under low-light conditions, mixing until complete dissolution, and fill-volume tolerance. The acetone and ethanol contents are monitored by gas chromatography with flame ionisation detection; the tincture is flammable and filled in explosion-proof areas. Alcoholic vehicles require cap-torque verification because ethanol loss through a poor seal changes the solvent ratio and may precipitate thiosalicylic acid. Topical preservative efficacy is established by USP <51> topical criteria; microbial limits are checked by Ph. Eur. 2.6.12 and 2.6.13. Clear polyethylene terephthalate containers are not used because light transmission and oxygen ingress accelerate photodegradation and mercury precipitation.

When tablets, capsules, powders and premixes operate below a water activity of 0.60, thiomersal addition creates a mercury load without a preservation benefit

Dry oral solid dosage forms and feed premixes with water activity <0.60 are outside the growth range for pathogenic bacteria, yeast and mould; USP <1112> establishes this boundary for nonsterile dosage forms. Consequently, Ph. Eur. 5.1.3 and USP <51> preservation challenge testing is not applicable to a tablet, hard capsule, powder or granular premix that remains dry throughout shelf life. If thiomersal is present in these formats, the technical justification shifts from preservation to an antiseptic or therapeutic claim, and no compendial monograph establishes an oral systemic antiseptic use for organomercurial compounds. Oral administration introduces systemic ethylmercury absorption and accumulation in renal and central nervous tissue, so a food-producing animal application requires residue depletion data and a species-specific maximum residue limit evaluation under European Commission Regulation (EU) No 37/2010 Table 1. Many jurisdictions prohibit mercury-based preservatives in oral feed and drinking water matrices. The practical quality controls for dry blends are blend uniformity, mercury assay and water activity; preservation is not a contributing variable. Published data for granulated oral thiomersal premixes in ruminant or monogastric feeds are limited.

Granular intermediates intended for reconstitution into a topical antiseptic solution are produced by wet granulation of anhydrous citric acid, sodium bicarbonate and lactose, with thiomersal dissolved in the binder fluid to improve content uniformity. The wet mass is dried at 35–40 °C to a loss-on-drying below 0.5% w/w, milled to a median particle size of 250–500 µm, and filled into foil-lined unit-dose sachets. The granule fill is pre-weighed to deliver a reconstituted concentration of 0.05% w/v in 20 L of purified water for companion animal wound irrigation or preoperative skin antisepsis. Dissolution and effervescent dispersion are specified as complete within 2 min at 25–30 °C; the citric acid-sodium bicarbonate couple generates carbon dioxide and avoids high-shear mixing. Content uniformity is measured by UV spectrophotometry or HPLC; acceptance limits of 90–110% of label claim are applied to unit-dose granules. The reconstituted solution is not automatically protected; if it is stored for more than 24 h, preservative efficacy must be verified separately according to Ph. Eur. 5.1.3. The sachet includes a desiccant because moisture ingress during storage lowers effervescent gas release and slows dispersion. This configuration is not intended for oral administration because a single sachet contains enough organomercurial to treat 20 L of topical solution, and accidental ingestion would produce systemic mercury exposure that has not been established as safe.

Mercury accountability in premix, feed and drinking water matrices for food-producing species

When a thiomersal pre-blend is handled in a feed mill or drinking water proportioner suite, total mercury is quantified by cold vapour atomic absorption spectrometry, inductively coupled plasma mass spectrometry, or direct combustion mercury analysis according to EPA Method 7473. Limits of quantification for mercury in mineral premix and compound feed matrices are typically 0.01–0.05 mg/kg, depending on sample digestion and spectral interference. Homogeneity sampling of a 0.01% w/w thiomersal pre-blend in a ribbon blender or V-blender requires 10 sampling locations and a relative standard deviation of ≤5% for the pre-blend to be valid for further dilution. The organomercurial powder is electrostatically adherent and requires a dedicated scoop, dust extraction, and spill containment to prevent cross-contamination of subsequent batches. Sulfur-containing ingredients such as methionine, cysteine and sulfite-treated molasses reduce ethylmercuric ion to elemental mercury, producing grey specks in the mix. Pelleting temperatures of 70–85 °C increase the risk of decomposition, but published stability data for thiomersal specifically in pelleted veterinary premixes are limited. Residue compliance is species-specific and must be checked against current maximum residue limits for mercury in muscle, liver and kidney. This application segment is a containment and analytical exercise, not a preservation application.